Relationship between brain metastasis and thyroid transcription factor 1
Abstract Brain metastases (BMs) are common in lung adenocarcinomas (ACs). Thyroid transcription factor 1 (TTF-1) is important in the diagnosis of AC. This study aimed to examine the relationship between TTF-1 and BM for the first time in literature. The data of 137 patients with AC that developed BM...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-29236-1 |
| _version_ | 1828041699956359168 |
|---|---|
| author | Engin Kut Serkan Menekşe |
| author_facet | Engin Kut Serkan Menekşe |
| author_sort | Engin Kut |
| collection | DOAJ |
| description | Abstract Brain metastases (BMs) are common in lung adenocarcinomas (ACs). Thyroid transcription factor 1 (TTF-1) is important in the diagnosis of AC. This study aimed to examine the relationship between TTF-1 and BM for the first time in literature. The data of 137 patients with AC that developed BM between 2009 and 2020 were retrospectively analyzed. A total of 137 patients, 120 (87.6%) male, and 17 (12.4%) female were examined. Their mean age was 59.78 ± 0.82 years. The Eastern Cooperative Oncology Group (ECOG) performance score was 0–1 (< 2) for 39 (28.5%) patients and 2–4 (≤ 2) for 98 (71.5%). TTF-1 was positive in 100 (73%) patients and negative in 37 (27%). More than five BMs were present in 102 (74.4%) patients and less than five in 35 (25.6%). All the patients received whole-brain radiotherapy. None of the patients was suitable for surgery or radiosurgery. The median survival time was 6.4 [95% confidence interval (CI), 5.67–7.1] months. The survival time was 7 (95% CI, 5.91–8.09) months for the TTF-1 (+) patients and 5.8 (95% CI, 4.1–7.5) months for the TTF-1 (−) patients. In the univariate analysis, there was a significant relationship between survival time and age (p = 0.047), TTF-1 (p = 0.024), and ECOG performance score (p = 0.002). The multivariance analysis revealed a significant relationship between survival and TTF-1 (p = 0.034) and ECOG score (p = 0.007). We found a correlation between survival time and ECOG performance score and TTF-1. TTF-1 can be used as a biomarker to monitor prognosis in the follow-up and treatment of patients with AC that develop BM. |
| first_indexed | 2024-04-10T17:18:59Z |
| format | Article |
| id | doaj.art-01fe7c58f67f4daaa928f6278500e84a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-10T17:18:59Z |
| publishDate | 2023-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-01fe7c58f67f4daaa928f6278500e84a2023-02-05T12:09:29ZengNature PortfolioScientific Reports2045-23222023-02-011311610.1038/s41598-023-29236-1Relationship between brain metastasis and thyroid transcription factor 1Engin Kut0Serkan Menekşe1Medical Oncology Clinic of Manisa State HospitalMedical Oncology Clinic of Manisa State HospitalAbstract Brain metastases (BMs) are common in lung adenocarcinomas (ACs). Thyroid transcription factor 1 (TTF-1) is important in the diagnosis of AC. This study aimed to examine the relationship between TTF-1 and BM for the first time in literature. The data of 137 patients with AC that developed BM between 2009 and 2020 were retrospectively analyzed. A total of 137 patients, 120 (87.6%) male, and 17 (12.4%) female were examined. Their mean age was 59.78 ± 0.82 years. The Eastern Cooperative Oncology Group (ECOG) performance score was 0–1 (< 2) for 39 (28.5%) patients and 2–4 (≤ 2) for 98 (71.5%). TTF-1 was positive in 100 (73%) patients and negative in 37 (27%). More than five BMs were present in 102 (74.4%) patients and less than five in 35 (25.6%). All the patients received whole-brain radiotherapy. None of the patients was suitable for surgery or radiosurgery. The median survival time was 6.4 [95% confidence interval (CI), 5.67–7.1] months. The survival time was 7 (95% CI, 5.91–8.09) months for the TTF-1 (+) patients and 5.8 (95% CI, 4.1–7.5) months for the TTF-1 (−) patients. In the univariate analysis, there was a significant relationship between survival time and age (p = 0.047), TTF-1 (p = 0.024), and ECOG performance score (p = 0.002). The multivariance analysis revealed a significant relationship between survival and TTF-1 (p = 0.034) and ECOG score (p = 0.007). We found a correlation between survival time and ECOG performance score and TTF-1. TTF-1 can be used as a biomarker to monitor prognosis in the follow-up and treatment of patients with AC that develop BM.https://doi.org/10.1038/s41598-023-29236-1 |
| spellingShingle | Engin Kut Serkan Menekşe Relationship between brain metastasis and thyroid transcription factor 1 Scientific Reports |
| title | Relationship between brain metastasis and thyroid transcription factor 1 |
| title_full | Relationship between brain metastasis and thyroid transcription factor 1 |
| title_fullStr | Relationship between brain metastasis and thyroid transcription factor 1 |
| title_full_unstemmed | Relationship between brain metastasis and thyroid transcription factor 1 |
| title_short | Relationship between brain metastasis and thyroid transcription factor 1 |
| title_sort | relationship between brain metastasis and thyroid transcription factor 1 |
| url | https://doi.org/10.1038/s41598-023-29236-1 |
| work_keys_str_mv | AT enginkut relationshipbetweenbrainmetastasisandthyroidtranscriptionfactor1 AT serkanmenekse relationshipbetweenbrainmetastasisandthyroidtranscriptionfactor1 |